Clinical and Translational Research
Copyright ©The Author(s) 2025.
World J Clin Oncol. Jan 24, 2025; 16(1): 94813
Published online Jan 24, 2025. doi: 10.5306/wjco.v16.i1.94813
Table 1 Clinical features of patients in this study
Discovery cohort
Validation cohort
Statistical methodP value
Prognostic model
(n = 262)(n = 113)
Survival time in daysWilcoxon0.5446
Median (IQR)1012 (547, 1712)1032 (394, 1562)
Aliveχ2 test0.5337
    Yes104 (39.69)41 (36.28)
    No158 (60.31)72 (63.72)
Immunotherapy efficacy model
(n = 18)(n = 8)
Sensitivity to immunotherapyFisher’s exact0.3945
    Yes9 (50.00)2 (25.00)
    No9 (50.00)6 (75.00)
Table 2 Overall performance of the ovarian cancer prognostic model

Discovery cohort
Validation cohort
AUC0.7268 0.6475
AUC 95%CI0.7258-0.72780.6466-0.6484
Table 3 Performance of the ovarian cancer prognostic model when truncated at 1 year, 2 years, and 3 years
Discovery cohort
Validation cohort
1 year
2 years
3 years
1 year
2 years
3 years
AUC0.75970.77340.74610.68270.7250.7087
AUC 95%CI0.6252-0.89420.6908-0.85600.6789-0.81340.5114-0.85410.6128-0.83730.6126-0.8049
Specificity0.78690.94810.90220.74510.79310.7895
Sensitivity0.66670.580.58970.63640.65380.6216
Accuracy0.77860.87790.80920.73450.76110.7345
NPV0.96970.90540.83840.950.88460.8108
PPV0.18750.7250.71880.21210.48570.5897
P value, goodness of fit0.66990.63040.43250.08260.10420.1084
Table 4 Overall performance of the ovarian cancer immunotherapy efficacy model

Discovery cohort
Validation cohort
AUC0.94440.9167
AUC 95%CI0.8333-1.00000.6667-1.0000
Specificity1.00000.8333
Sensitivity0.88891.0000
Accuracy0.94440.8750
NPV0.90001.0000
PPV1.00000.6667
P value, goodness of fit0.37080.1175